NEW YORK (360Dx) – Novacyt said today that its Lab21 Products protein diagnostics division has entered an agreement to acquire Omega Diagnostics' infectious disease business for up to £2.2 million ($2.9 million).

The acquisition fee consists of £1.8 million upon completion, £175,000 paid after 12 months and upon completion of technology transfer, and £200,000 paid upon the successful accreditation to certain standards of an Omega Diagnostics production facility in Axminster, UK.